Riquent: Withdrawal of the marketing authorisation application
On 13 October 2006, La Jolla Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Riquent, for the treatment of lupus nephritis.
|International non-proprietary name (INN) or common name||
|Date of withdrawal||
|Company making the application|
La Jolla Limited withdraws its marketing authorisation application for Riquent (PDF/25.39 KB)
First published: 13/10/2006
Last updated: 13/10/2006
Withdrawal letter : Riquent (PDF/22.29 KB)
First published: 11/10/2006
Last updated: 11/10/2006
Questions and answers on the withdrawal of the marketing application for Riquent (PDF/39.66 KB)
First published: 18/10/2006
Last updated: 18/10/2006
Related information on withdrawals
A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter (withdrawal letter Doc. type, leave the 'Author' in properties blank).
An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').